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 Merkel cell carcinoma (MCC) is a rarely occurring skin cancer of high malignancy. It develops, most probably, from the 
neuroendocrine cells (Merkel’s cells). The most frequent location of this cancer is the skin of the head and neck (44–48% 
of cases), and then in the skin of the upper limbs (about 19% of cases) and then the lower limbs (16–20% of cases). The 
aetiology of this cancer is unknown, yet some role in its pathogenesis is played by ultraviolet light and immunosuppression. 
The basis of therapy in cases with locoregional spread is surgical intervention, whilst in more advanced cases, an effective 
systemic treatment is possible with the use of molecularly targeted therapies. This paper presents the current treatment 
possibilities in patients with  Merkel cell carcinoma.
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Introduction
Merkel cell carcinoma (MCC) is a rarely occurring skin cancer 
of high malignancy. It develops, most probably, from the neu-
roendocrine cells (Merkel’s cells) [1, 2].
The incidence of MCC is low, evaluated to be 0.25– 
–0.32/100 000 people per year. The prevalence is higher among 
men than women (at a ratio of 1.5:1). This cancer is markedly
more common in representatives of the white race than in
other races. The risk of developing MCC increases with age
– the frequency of MCC in patients below 50 years of age is
very low. The most frequent location of this cancer is the skin 
of the head and neck (44–48% of cases), the skin of the upper 
limbs (about 19% of cases and then the lower limbs (16–20% 
of cases) [3, 4]. Merkel cell carcinoma very rarely develops
within the mucous membranes. There are also patients in
whom – though with a lack of detectable primary focus – the 
metastases of Merkel cell carcinoma are found in the lymph
nodes [5]. According to some findings, such cases may account 
for 10%–15% of all MCC cases. Observational studies in the USA 
population seem to suggest that the incidence of Merkel cell 
carcinoma is increasing, which may be connected with the
ageing population and be an outcome of developments in 
histopathological diagnostics [6]. 
Aetiology 
The aetiology of this cancer is unknown though there are well 
identified factors which predispose for MCC. These factors 
comprise first and foremost:
• Exposure to ultraviolet irradiation (UV) – whether natural
or artificial, e.g. after treatment for psoriasis with the use
of phototherapy and psolaren ultraviolet A – PUVA) [7, 8];
• Immunocompromising diseases, such as:
a) HIV/AIDS infection (the risk of developing MMC is
increased 11-fold) [9],
b) immunosuppression after an organ transplant (the
risk of developing MMC is increased 5-fold) [10, 11],
c) chronic lymphocytic leukaemia;
• Some viral infections, with the most significant being a po-
lyoma infection – the type characteristic for MCC: Merkel
cell polyomavirus (MCPyV) [12, 13]. The role of MCPyV in
the pathogenesis of MCC is unclear. Viral DNA is detected 
in 60–80% people affected with MCC.  At the same time,
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in people with the confirmed presence of the virus, longer 
overall survival  is observed in comparison with the group 
of patients without the viral infection  [12, 14].
Diagnostics 
Merkel cell carcinoma (MCC) most frequently takes the form 
of a relatively rapidly expanding tumour or solid infiltration 
on the skin, often of a red to violet colour. Ulceration is rare. 
Sometimes the tumour spreads quickly through the pathways 
of local lymphatic vessels, which in turn leads to the develop-
ment of satellite foci. The tumour is not usually accompanied 
by any disorders – it is painless in the majority of cases [15]. 
This unspecific clinical picture has the effect that MCC is rarely 
suspected before the result of a histopathological assessment 
of material from an excisional biopsy or specimen.
In English-language publications, a mnemotechnical acro-
nym has been proposed to facilitate MCC diagnostics – AEIOU: 
A – asymptomatic; 
E – expanding rapidly; 
I – immunosuppressed; 
O – older than 50 years; 
U – UV-exposed skin.
Only 7% of MCC patients meet all the above criteria, but in 
about 90% of patients, at least 3 of these criteria can be found [15].
The clinical picture and a short interview suggestive of a 
lesion of a malignant nature, may be an indication for an exci-
sional biopsy performed in accordance with generally binding 
principles. Microscopic assessment of the excised tumour 
allows for diagnosis. The pathological diagnosis is facilitated 
by immunohistochemistry. The histopathological image of 
the lesion shows a small cell cancer (often the expression of 
cytokeratin 20 and neuroendocrine markers and a lack of TTF-1 
expression characteristic of small cell lung cancer [SCLC] are 
observed; PD-L1 expression is present in about 50% of cases).
In order to evaluate the stage of the disease in the cases 
where a Merkel cell carcinoma tissue pattern is found, it is 
recommended to perform a physical examination and ima-
ging diagnostics. Depending on individual indications, these 
would be an X-ray, computed tomography (CT), magnetic 
resonance (MR), possibly in conjunction with pathological or 
cytological diagnostics (fine needle aspiration biopsy) of the 
suspicious foci.
In some cases, where the histopathological diagnosis is 
doubtful and there is a suspicion of an extra-dermal primary 
focus of the cancer (skin metastases of the tumours other than 
MCC, e.g. SCLC), there may be some indications to expand the 
diagnostics process with positron-emission tomography (PET) 
in conjunction with CT.
Clinical stages, prognosis 
Currently the eighth edition of the tumour classification, as es-
tablished by the American Joint Committee on Cancer (AJCC) 
is in use. This classification is based on typical TNM criteria 
(tumour-node-metastases) (table I and II) [5, 16–18]. It seems, 
however, that the factors with the largest prognostic value 
are the primary tumour size, the presence of metastases at 
the moment of diagnosis and the scope of the involvement 
of lymph nodes.
The ten-year overall survival in MCC patients is estimated 
to be 65% in women and 50.5% in men (57% on average for 
Table I. Classification of MCC stages (2017)
Primary tumour (T)
TX Primary tumour not possible for evaluation 
T0 No presence of primary tumour (e.g. node metastases 
with unknow primary focus)
Tis cancer in situ
T1 Maximum tumour diameter up to 2 cm
T2 Tumour diameter above 2 cm up to 5 cm inclusive 
T3 Maximum tumour diameter above 5 cm
T4 Tumour infiltration to the bones, muscles, fascia or 
cartilage 
Regional lymph nodes (N)
NX Regional lymph nodes not possible for evaluation
N0 No metastases in regional lymph nodes 
N1 Metastases in regional lymph node(s)
N1a (sn) Micro-metastases (detected in the sentinel node biopsy)
N1a Clinically not detectable metastasis found in 
lymphadenectomy 
N1b Macro-metastases (found in clinical or radiological 
assessment), confirmed in microscopic evaluation 
N2 Metastases in transit without the metastases in regional 
lymph nodes 
N3 Metastases in transit with the metastases in regional lymph 
nodes 
Distant metastases (M)
M0 No metastases 
M1 Metastases in distant organs (other than regional lymph 
nodes)
M1a Metastases in the skin, subcutaneous tissue and lymph 
nodes 
M1b Lung metastases 
M1c Other locations of metastases
Table II. Pathological stages/prognostic groups
Stage T N M
0 Tis N0 M0
I T1 N0 M0
IIA T2–T3 N0 M0
IIB T4 N0 M0
IIIA T0 N1b M0
IIIA Each T N1a (sn)/ N1a M0
IIIB Each T N1b–N3 M0
IV Each T Each N M1
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all patients). Depending on the size of the primary tumour, the 
10-year survival rate is as follows: 
• for tumours with a 2 cm diameter or smaller – 61%
• larger than 2 cm – only 39% [5]
5-year survival is the following:
• 37% – for patients with locoregional spread (stage IIIb)
• 16% – for patients with distant metastases [19].
Treatment
The basis of therapy in cases with a locoregional spread is sur-
gical intervention. The treatment of an MCC should be carried 
out in highly specialised centres [17, 20, 21].
Clinical stage I and II 
Where there is a lack of detectable metastases in the regional 
lymph nodes, a sentinel node biopsy should be considered 
with a wide scar excision (up to a margin of at least 1–2 cm). 
This is prompted by the observation that metastases in the 
sentinel nodes occur in 25–35% of patients even when clinical 
symptoms of metastases are not present. The risk of developing 
micro-metastases increases significantly in patients with a pri-
mary focus with a diameter measuring 1cm or more [22, 23]. 
The majority of recommendations suggest that local surgi-
cal treatment should be combined with radiotherapy, although 
the efficiency of such an approach has not been confirmed 
in randomised trials. However, the recently published results 
of a meta-analysis of the available observations suggest that 
radiotherapy slightly improves the overall survival rate and 
significantly affects the locoregional control of the tumour. The 
results of the meta-analysis show that patients with an MCC 
in stage T2 or later benefit from the combination of surgery 
with radiotherapy  [24].
Clinical stage III 
The presence of metastases in regional lymph nodes (both 
micro- and macro-metastases; stage III) is an indication of the 
resection of the regional lymph nodes. 
In spite of the lack of evidence coming from studies with 
patient randomisation, the majority of retrospective analyses 
point to an improvement of loco-regional control and  patient 
survival after the application of adjuvant radiotherapy to the 
bed created after the resection of regional lymph nodes  (at 
a dose of 50–60 Gy) [25, 26].
Some authors postulate that in patients with a massive 
involvement of the lymph nodes, chemotherapy should also 
be considered. However, no typical systemic therapy in this 
group of patients has been established – the treatment can 
be carried out both preoperatively and postoperatively. In 
some centres, lymphadenectomy in these patients is perfor-
med between chemotherapy cycles. The published data do 
not allow, however, for a definitive conclusion as to whether 
systemic therapy affects the improvement of overall survival 
in this group [26–28].
Preliminary results from the application of checkpoint 
inhibitors in preoperative treatment of an MCC seem to be 
promising. In 2018, the results of a I/II phase trial of the use of 
nivolumab in neoadjuvant treatment of MCC patients in stage 
IIa–IV (CheckMate 358) were published. The trail comprised 
29 adult patients who had not been previously systemically 
treated for an MCC. In the majority of patients, the presen-
ce of polyoma virus (MCPyV; 71.4%) was found. The PD-L1 
expression was established in 20 patients and in 30% of them 
the expression was on the level of at least 1%. The patients 
received a nivolumab infusion at a dose of 240 mg on day 1 
and 15 (counting from the commencement of therapy), and 
then on day 29, surgery was performed. Out of 27 patients who 
underwent surgery, 9 received post-operative radiotherapy 
and 1 patient received nivolumab for one year on account 
of the progression of the disease. After a median follow-up 
period of 67.1 weeks, in 40% of the 25 patients, radiological 
assessment revealed a decrease of the lesions by about 30%. 
No correlation between the treatment response and MCPyV 
status and PD-L1 expression was found. Although the radiolo-
gical assessment revealed only one complete response, in the 
pathological assessment, a complete pathological response 
was found in 47% patients and a major pathological response 
(≤10% of live tumour cells) in 18% patients. In some patients, 
the response which was achieved allowed for surgery with 
a  smaller scope. At the same time, no median progression 
free survival (PFS) or median overall survival (OS) were gained. 
The rates of progression free survival after 6 and 12 months 
were 92.1 and 72.6% respectively. The survival rates after 18 
and 24 months were 100 and 75% respectively. In none of the 
patients with complete or major pathological response was 
disease recurrence observed. 
The drug safety profile was compliant with the results 
seen in other clinical trials.  No adverse events of grade 5 or 
severe were observed. In none of the patients qualified for 
surgical intervention was it necessary to postpone the surgery 
on account of poor tolerance for the systemic treatment [29]. 
 Currently there is a multi-centre, phase III, double blinded, 
placebo-controlled clinical trial being carried out with the 
objective to evaluate the efficacy of avelumab  in the adjuvant 
treatment of MCC patients after surgical treatment  (with or 
without radiotherapy) with clinically confirmed metastases 
in regional lymph nodes (NCT03271372). The patients are 
randomised (ratio 1:1) either to a group receiving avelumab at 
a dose of 10 mg/kg of body mass or to a placebo group. The 
primary endpoint is recurrence free survival [30].
Clinical stage IV 
In cases of advanced disease, the treatment is palliative. In 
patients who are in a satisfactory condition, palliative che-
motherapy might be considered although there is no data 
which could confirm the effect of such treatment on overall 
survival. Additionally, the justification for immunotherapy sho-
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uld be evaluated [17, 31] – provided that it is available – as 
there are data pointing to its efficacy. On account of the high 
activity of immune system checkpoint inhibitors  (anti-PD-1 
and anti-PD-L1) in the treatment of metastatic MCC, current 
recommendations suggest the application of these drugs as 
treatment of choice (a fact which has been confirmed by phase 
II clinical trials) [32]. 
Many observations point to the chemosensitivity of MCC 
(although the response does not exceed 8–10 months and 
the rate of long-term overall survival stands at 0–18%). The 
most frequently used therapeutic regimes are chemotherapy 
with cisplatin, doxorubicin and vincristine or etoposide as well 
as 5-fluorouracil or cyclophosphamide. In cases where it is 
justified, palliative surgical interventions and/or radiotherapy 
may also be applied.
In 2019, the results of a retrospective analysis of treatment 
patterns was applied to patients with newly diagnosed MCC, 
treated between October 2013 and January 2018. Out of  120 
patients treated systemically within the first line of treatment, 
17%, 45% and 38% patients were treated with checkpoint 
inhibitors, chemotherapy applied according to the NCCN gu-
idelines or another type of chemotherapy respectively. The 
most frequently used chemotherapy patterns were carboplatin 
with etoposide and cisplatin with etoposide. Only 33% patients 
systemically treated in the first line commenced the second 
line of treatment [33].
Moreover, the results of  clinical studies into the use of 
avelumab, pembrolizumab and nivolumab in the treatment 
of advanced MCC have been published.
A single-arm second phase clinical trial, JAVELIN Merkel 
200, showed the efficacy of  avelumab in the treatment of MCC 
with metastases after the failure of systemic chemotherapy; 
avelumab was administered at a dose of 10 mg/kg of body 
mass intravenously every two weeks until the moment of pro-
gression or unacceptable toxicity. The objective response rate 
(ORR) was 31.8% (95% confidence interval (CI): 21.9–43.1%; 28 
patients), including 8 complete responses (9%) and 20 partial 
responses  (23%). Additionally, in 9 patients (10%) disease 
stabilisation was observed [34]. The treatment responses had 
a lasting effect and, at the moment of analysis, they persisted 
in 23 (82%) patients. The length of the response was at least 
6 months in 92% of cases. The median PFS was 2.7 months 
(95% CI: 1.4–6.9), and the rate of patients free from disease 
progression after 6 months was 40%. The PFS curves reached 
plateau. The survival rate after 6 months was 69% (95% CI: 
58–78), and the median OS – 11.3 months (95% CI: 7.5–14.0). 
Objective responses were obtained in the following patients:
• 20 out of 58 patients (34.5%) with PD-L1 expression,
•  3 out of 16 patients (18.8%) PD-L1 (–),
• 12 out of 46 patients (26.1%) MCPyV (+),
• 11 out of 31 patients (35.5%) MCPyV (–). 
More responses were obtained in patients who had pre-
viously undergone only one line of treatment. Avelumab was 
generally well tolerated. Treatment related adverse events 
occurred in 62 (70%) out of 88 patients. Updated results with 
median follow-up periods of 18 months and 24 months pu-
blished in  2018, confirm the efficacy of avelumab for this 
indication. On the basis of an analysis of the data from 88 
patients followed up for 29.2 months (24.8–38.1) it was obse-
rved that the median OS was 12.6 months (95% CI: 7.5–17.1), 
with the 2-year survival rate being 36% (50% survival after 1 
and 39% after 1.5 years). The median treatment period was 
3.9 months (0.5–36.3). The rate of confirmed ORR was 33.0% 
(95% CI: 23.3–43.8; CR observed in 11.4% patients) and this 
remained on the same level as in the case of the analyses car-
ried out after one year and 1.5 years of follow-up. The median 
response period was not reached (2.8–31.8 months; 95% CI: 
18.0 – not reached). The long-term responses to avelumab 
treatment determine stable PFS values in evaluations after 
1 year of observation  (29%), after 1.5 years (29%) and after 2 
years of follow-up (26%). Clinical activity persisted irrespecti-
vely of PD-L1 expression status and the presence of polyoma 
virus. The tolerance profile of avelumab was consistent with 
those already existant. In 67 patients (76.1%) treatment related 
adverse events were observed and in 10 patients (11.4%) they 
were at least 3 grade. In 20 patients (22.7%) adverse events 
related to immunological activity of avelumab were observed. 
No deaths connected with the treatment occurred [35, 36]. 
The second phase trial, JAVELIN Merkel 200, also resulted in 
the registration for the first line of treatment of advanced MCC. 
The data concerning the survival of these patients, published 
in 2018, point to a mean survival rate of 49.9 months (6.3; 179.4) 
with the one year and five year survival rates being 66% and 
23% respectively [37]. So far no predictive factors of avelumab 
treatment response of  MCC patients  have been established [38].
In  2017, during the annual conference of the American 
Society of Clinical Oncology (ASCO), the preliminary results 
of part of the second phase trial with the use of avelumab 
(JAVELIN Merkel 200) in the first line of treatment of advanced 
MCC were presented [39]. In 16 patients, after a follow-up pe-
riod of at least 3 months, the response rate was 62.5% (in 10 
patients 3 complete remissions and 7 partial remissions were 
observed), and all these responses persisted at the moment 
of the last evaluation. The updated results of part B of this 
trial confirmed that 77.8% (14 out of 18) treatment responses 
persisted and the response duration in 83% cases was longer 
than 6 months (95% CI: 46–96%) [40]. In 29 patients, the safety 
of the therapy was evaluated: adverse events with minimum 
toxicity grade 3 occurred in 5 patients (17.2%), and this was 
the reason for the termination of the treatment (2 patients 
developed reactions related to the administration of the drug, 
such as increased activity of aspartate aminotransferase and 
alanine aminotransferase, cholangitis, paraneoplastic syndro-
me and gait disorders). According to recently updated analysis, 
in 8 patients in total there were grade 3 adverse events related 
to the immunology system (20.5%). 
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A second phase clinical trial published in 2016 showed 
the efficacy of pembrolizumab (anti-PD-1 antibody) in the 
treatment of the stage IIIB–IVC MCC patients, who were 
systemic treatment naïve [41]. This was a multi-centre cli-
nical trial (Cancer Immunotherapy Trials Network-09/Key-
note-017), which enrolled 50 patients with advanced MCC. 
They received pembrolizumab at a dose of 2 mg/kg of body 
mass every 3 weeks for up to 2 years. The median age of the 
subjects was 70.5 years. In 64% the tumour was MCPyV(+). 
The efficacy evaluation was performed on the basis of RECIST 
1.1. criteria; the ORR totalled 56% (CR 24%, PR 32%; 95% CI: 
41.3–70.0%): the ORR in the patients in the group MCPyV(+) 
was 59%, whilst in those in the group MCPyV(–) it was 53%, 
with a  median follow-up of 14.9 months (range 0.4–36.4 
months). Among the 28 patients in whom a treatment re-
sponse was observed, the median response duration was 
not reached (range 5.9–34.5 months). The PFS ratio after 
24 months was 48.3% with a median PFS of 16.8 months, 
whilst OS rate after 24 months was  68.7%, and the median 
OS was not reached. The presence of polyoma virus did not 
correlate with ORR, PFS or OS. Some trend for better results 
concerning PFS and OS was observed in patients with PD-
L1 expression. Treatment related adverse events ≥G3 were 
found in 28% of patients (14 out of 50) and in 14% (7 out of 
50) these events required the termination of the treatment. 
One treatment related death occurred [42].
Similarly, in the avelumab trial, a tendency towards gre-
ater treatment response was observed where the number of 
previous treatment lines was smaller. This shows (taking into 
consideration the pembrolizumab trials), that immunotherapy 
in MCC should be the treatment of choice in the first line of 
therapy. In all the presented trials, the responses were found in 
both MCPyV-positive and negative patients, and, as was con-
firmed, this  type of treatment may also be applied to elderly 
patients (a fact which is vital given that this disease develops 
mostly among people of advanced age). 
Currently, immunotherapy with anti-PD-1/anti-PD-L1, in 
accordance with Polish and international recommendations, 
makes for standard systemic treatment in patients with unre-
sectable/metastatic  MCC [32, 43], and avelumab, registered for 
this indication in the European Union, is available in Poland as 
part of the Emergency Access to Therapy programme (Ratun-
kowy Dostęp Terapii Lekowej) in conjunction with a positive 
opinion on the part of AOTMiT (the Agency for Health Tech-
nology Assessment and Tariff System).   
Additionally, preliminary results of the first and second 
phase trials with nivolumab administered in a group of 22 
patients with MCC. In these people, the ORR rate was 68% 
after the 26-week follow-up period (with a scope of 5–35 
weeks) and it was slightly larger in patients who had not been 
systemically treated previously (71%, n = 14), in comparison 
with those who had  been previously treated (63%, 1 or 2 lines 
of previous treatment, n = 8) [44].
The treatment of local relapses and recurrences 
in regional lymph nodes 
The most frequent recurrence form is a local relapse. This af-
fects about 30% of patients treated surgically (postoperative 
radiotherapy decreases this rate to about 11%) [45].
Local relapses may be treated like a primary MCC with cor-
rect reference to the clinical stage (I–III). If possible, the tumour 
foci should be resected with a margin of healthy tissues, with 
adjuvant radiotherapy, provided that this was not applied for 
the treatment of the primary focus. Disease recurrence makes 
for a bad prognosis, and for this reason systemic adjuvant 
treatment should also be considered even though there still 
is no evidence for its effectiveness.
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